Skip to main content

Table 2 Participant demographic and selected clinical characteristics (N = 97)

From: Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs

  M (SD) or % (n) Range
Demographic characteristics
 Age, years 42.2 (10.3) 21–63
 Education, years 11.4 (2.3) 6–18
 Female 27% (26)  
 HIV +  6% (6)  
 Hepatitis C diagnosisa 14% (14)  
Race/ethnicity
 Non-Hispanic White 22% (21)  
 Non-Hispanic Black/African-American 24% (23)  
 Latinx 52% (50)  
 Other 2% (3)  
Opioid use characteristics
 SR heroin in last 30 days 87% (79)  
 SR other opiates in last 30 days 33% (30)  
 UT opiates 98% (92)  
 Lifetime opioid use disorder 100% (97)  
Cannabis use characteristics
 SR cannabis in last 30 days 44% (40)  
 UT cannabis 25% (24)  
 Lifetime cannabis use disorder 44% (42)  
Stimulant use characteristics
 SR cocaine in last 30 days 40% (36)  
 UT cocaine 28% (27)  
 Lifetime cocaine use disorder 59% (57)  
 SR amphetamines in last 30 days 2% (2)  
 UT amphetamines 1% (1)  
Sedative use characteristics
 SR alcohol in last 30 days 41% (37)  
 SR alcohol to intoxication in last 30 days 24% (22)  
 Lifetime alcohol use disorder 54% (52)  
 SR sedatives in last 30 days 23% (21)  
 UT benzodiazepines 11% (11)  
 Lifetime sedative use disorder 28% (27)  
Psychological characteristics
 BDI-II Total Score 15.4 (10.6) 0–45
  Minimal total score ≤ 13 50% (45)  
  Mild total score 14 and 19 17% (15)  
  Moderate total score 20 and 28 23% (22)  
  Severe total score 29 and 63 10% (9)  
 CIDI lifetime major depressive disorder 37% (35)  
  1. an = 85. SR = Self-report use from Addiction Severity Index; UT = Urine toxicology at baseline visit; BDI-II = Beck Depression Inventory – II; CIDI = Composite International Diagnostic Interview–Version 2.1